Comparative immunogenicity assessment: A critical consideration for biosimilar development

Bioanalysis

Volumn 7, Issue 3, 2015, Pages 373-381

  Liu, Patrick M ^a   Zou, Linglong ^a   Sadhu, Chanchal ^b   Shen, Wenyan D ^c   Nock, Steffen ^d  

^a TEVA PHARMACEUTICALS   (Israel)

^b MEDIMMUNE   (United States)

^c NGM Biopharmaceuticals   (United States)

^d Teva Biologics R and D   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; DRUG ANTIBODY; EPITOPE; REAGENT;

ANTIBODY DETECTION; COMPARATIVE STUDY; DRUG DESIGN; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; REVIEW; ANIMAL; DRUG DEVELOPMENT; DRUG EFFECTS; IMMUNITY; PROCEDURES;

ANIMALS; BIOSIMILAR PHARMACEUTICALS; DRUG DISCOVERY; HUMANS; IMMUNITY;

EID: 84923354566     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.14.311     Document Type: Review

References (23)

1. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products. www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003517.pdf.
2. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1) (Draft). www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/05/WC500127960.pdf.
3. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (Draft). www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003920.pdf.
4. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (Revision). www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/04/WC500089474.pdf.
5. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Draft guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human follicle stimulating hormone (r-hFSH) (Draft). www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/11/WC500117986.pdf.
6. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues (Draft). www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/04/WC500165988.pdf.
7. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Draft guideline on similar biological medicinal products containing interferon beta (Draft). www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/01/WC500120652.pdf.
8. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing monoclonal antibodies (Draft). www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/06/WC500128686.pdf.
9. US Food and Drug Administration. Guidance for industry-quality considerations in demonstrating biosimilarity to a reference protein product (Draft Guidance). www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ ucm291134.pdf.
10. US Food and Drug Administration. Guidance for industry-scientific considerations in demonstrating biosimilarity to a reference product (Draft Guidance). www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ ucm291128.pdf.
11. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003946.pdf.
12. US Food and Drug Administration. Guidance for industry-Assay development for immunogenicity testing of therapeutic proteins (Draft guidance). www.fda.gov/downloads/Drugs/ Guidances/UCM192750.pdf.
13. Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48, 1267-1281 (2008).
14. Cai XY, Gouty D, Baughman S et al. Recommendations and requirements for the design of bioanalytical testing used in comparability studies for biosimilar drug development. Bioanalysis 3(5), 535-540 (2011).
15. Cai XY, Thomas J, Cullen C et al. Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development. Bioanalysis 4(17), 2169-2177 (2012).
16. European Bioanalysis Forum. Outcome of EBF Survey on Biosimilars. http://bcn2012.europeanbioanalysisforum.eu/slides/ day%202/ii%20biosimilars/2-munday.pdf.
17. US Food and Drug Administration. Guidance for industry-immunogenicity assessment for therapeutic proteins (Draft guidance). www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ ucm338856.pdf.
18. Christine HC, Mirakhur B, Chan E et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-A-1, 3-Galactose. N. Engl. J. Med. 358(11), 1109-1117 (2008).
19. Barbosa MDFS. Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters. Drug Discov. Today 16(7-8), 345-353 (2011).
20. Hoffmann S, Cepok S, Grummel V et al. HLA-DRB1 0401 and HLA-DRB1 0408 are strongly associated with the development of antibodies against interferon-b therapy in multiple sclerosis. Am. J. Hum. Genet. 83, 219-227 (2008).
21. Qiu ZJ, Ying Y, Fox M et al. A novel homogeneous biotin-digoxigenin based assay for the detection of human anti-Therapeutic antibodies in autoimmune serum. J. Immunol. Methods 362, 101-111 (2010).
22. Jaki T, Lawo JP, Wolfsegger MJ et al. A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays. J. Pharm. Biomed. Anal. 55(5), 1148-1156 (2011).
23. Shankar G, Arkin S, Cocea L et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J. 16(4), 658-673 (2014).